Dorn, Christoph http://orcid.org/0000-0002-2560-9598
Petroff, David
Kratzer, Alexander
Kees, Frieder
Kloft, Charlotte
Zeitlinger, Markus
Wrigge, Hermann
Simon, Philipp
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (FKZ: 01E01001)
Universität Regensburg
Article History
Accepted: 17 July 2022
First Online: 9 August 2022
Declarations
:
: Open Access funding enabled and organized by Projekt DEAL. This trial was funded by the Federal Ministry of Education and Research, Germany (Integrated Research and Treatment Centre IFB “Adiposity Diseases”, FKZ: 01E01001), and by departmental funding.
: CK reports research grants for PharMetrX, DDMoRe, FAIR. HW received grants from Pfizer (Investigator Initiated Trial Program, Berlin, Germany) and InfectoPharm (Heppenheim, Germany), both for the clinical microdialysis trial. HW reports lecture fees from InfectoPharm (Heppenheim, Germany), MSD (Konstanz, Germany), Getinge (Rastatt, Germany) and Medtronic (Meerbusch, Germany) and consultant honoraria from Dräger Medical (Lübeck, Germany) and Liberate Medical (Crestwood, KY, USA). PS reports lecture fees from InfectoPharm (Heppenheim, Germany). The other authors have no conflicts of interest to declare.
: PS, HW, DP, FK and MZ contributed to the study conception and design. PS and DP collected the data. CD, AK and FK performed bioanalysis. CD and FK performed pharmacokinetic and statistical analysis. CD and FK drafted the manuscript; DP, AK, CK, MZ, HW and PS revised and edited the manuscript.
: Approval for the trial was obtained from the Leipzig University ethics committee (121/13-ff) and the Federal Institute for Drugs and Medical Devices of Germany (BfArM).
: Prior written informed consent was obtained from all study participants.
: Not appicable.
: Not applicable.
: Data are available on reasonable request.